Dopamine transporter ligands: recent developments and therapeutic potential.

Area of Science:

• Neuroscience
• Pharmacology
• Medicinal Chemistry

Background:

• The dopamine transporter (DAT) is a crucial target for treating central nervous system disorders.
• Developing novel DAT ligands is essential for advancing pharmacotherapies.
• Existing DAT inhibitors have shown potential in various therapeutic areas.

Purpose of the Study:

• To review recent advancements in DAT ligand development.
• To highlight novel ligands from diverse chemical classes.
• To discuss the therapeutic potential and preclinical/clinical evaluation of these ligands.

Main Methods:

• Review of scientific literature on DAT uptake inhibitors.
• Categorization of ligands based on chemical structure (e.g., 3-phenytropane, 1,4-dialkylpiperazine).
• Summary of preclinical studies (e.g., cocaine self-administration in non-human primates) and clinical trials.

Main Results:

• Several novel DAT ligands from various classes have been synthesized and characterized.
• Some compounds demonstrated efficacy in reducing stimulant self-administration in animal models.
• GBR 12,909 advanced to a Phase 1 clinical trial.

Conclusions:

• Recent developments in DAT ligand discovery offer promising therapeutic avenues.
• Targeting DAT is a viable strategy for conditions like ADHD, Parkinson's disease, obesity, and stimulant abuse.
• Further research and clinical evaluation are warranted for promising DAT-targeting compounds.